BUFFALO, N.Y., Feb. 17, 2010 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI), an innovator of drugs for treatment of cancer and protection of normal tissues from exposure to radiation, is holding a press conference to discuss business and clinical advances.

When: February 24, 2010, 12:30 pm EST

Where: NASDAQ MarketSite, 4 Times Square, New York, NY

RSVP required for building security: 212 699-0999 or christina.flood@muncmedia.com

From National Defense Magazine, the offical publication of the NDIA.

"If a one-kiloton nuclear device exploded in New York City, it would kill or sicken millions of people because there are no effective and non-toxic treatments for victims of acute radiation syndrome.

But a new Pentagon-funded drug currently proceeding through human trials potentially could help save many of those lives. Cleveland BioLabs Inc. of Buffalo, N.Y. has developed a radiation countermeasure, called Protectan CBLB502.

When given as a single injection, as many as 80 percent of those exposed to total body irradiation could survive (Inside Science & Technology, August 2009)."

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2009.

CONTACT: Cleveland BioLabs, Inc.
         Media Contact:
         Rachel Levine, Director Corporate Development & Communications
         (646) 284-9439